NEW YORK, NY / ACCESSWIRE / June 18, 2018 / Biotech stocks Geron Corporation and BioMarin Pharmaceutical were both rising in Friday?s trading session with gains of almost 10% by the close of the day. While Geron had no significant news, BioMarin announced last week that it has dosed its first participant in a global phase II study for vosoritide, an experimental drug for the treatment of achondroplasia.

RDI Initiates Coverage on:

Geron Corporation
https://www.rdinvesting.com/report/?ticker=GERN

BioMarin Pharmaceutical Inc.
https://www.rdinvesting.com/report/?ticker=BMRN

Geron Corporation shares closed up 9.74% on nearly 7.2 million shares traded this past Friday. There was no remarkable news to explain the big jump in Friday's trading session. It was in May that the company and Johnson & Johnson announced that imetelstat's ongoing lower risk myelodysplastic syndromes (MDS) study was selected for an oral presentation at the 23rd Congress of the European Hematology Association this month. Sunday was the last day of the event. The company had an abstract describing clinical data regarding the telomerase inhibitor imetelstat selected for an oral presentation. The abstract contains updated data (as of January 2018) from the first 32 patients enrolled in Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes (MDS) being conducted by Janssen Research & Development, LLC.

Access RDI's Geron Corporation Research Report at:
https://www.rdinvesting.com/report/?ticker=GERN

BioMarin Pharmaceutical Inc. shares closed up 8.47% this past Friday on about 3.9 million shares traded. The company announced last Thursday that it has dosed the first participant in a global Phase 2 study for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in infants and young children with achondroplasia. Achondroplasia is a genetic disorder that causes dwarfism in infants and toddlers. The company's President of Worldwide Research and Development, Hank Fuchs, M.D. stated, "Vosoritide represents an innovative therapy to treat the underlying cause of achondroplasia. At the molecular level, vosoritide corrects the signaling process that determines skeletal growth and proportionality of bones, while the body is still growing. We are pleased to have initiated this study in the youngest people with achondroplasia and are grateful to the children and their families who have been participating in our ongoing studies and those who are now participating in this Phase 2 study." Vosoritide has been granted orphan drug designation in both the United States and Europe.

Access RDI's BioMarin Pharmaceutical Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=BMRN

Our Actionable Research on Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com